Previous 10 | Next 10 |
Anika Therapeutics (NASDAQ: ANIK ): Q3 GAAP EPS of $0.64 beats by $0.25 . More news on: Anika Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Total Revenue Increases 11% and Net Income Increases 21% Year-over-Year Company Raises Full Year 2019 Revenue and Earnings Guidance Executing Five-Year Strategic Plan Focused on Joint Preservation and Restoration Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated...
Small-cap stocks have been weighed down by ongoing uncertainty associated with trade deals and interest rate policy, making it harder than ever to spot potential winners and limit risk. Although small-cap stocks could face headwinds if the economy decelerates, there are specific industries and...
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid ("HA") technology platform , today announced plans to showcase its osteoarthritis pain management and joint preservat...
Industry veteran brings extensive experience leading global regulatory, quality, and clinical affairs teams Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated company, focused on developing regenerative therapies leveraging its proprietary hyaluronic acid ("HA") technolog...
Small-cap stocks have underperformed large-cap stocks, and recent manufacturing and services industry data increases concerns that profits could stagnate. The risk of decelerating economic activity to small-cap stocks shouldn't be ignored, but that doesn't mean there aren't sectors, industries...
Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its third-quarter 2019 financial results after the close of the market on Thursday, October 24, 2019 and hold its investor conference call on the same day, Thursday, October 24, 2019, at 5:00 p.m. ET to ...
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated regenerative therapies company leveraging its proprietary hyaluronic acid ("HA") technology platform , today announced plans to showcase its osteoarthritis pain management and joint preservation and restoration therapies at the ...
Anika Therapeutics ( ANIK -0.1% ) commences the U.S. commercial soft launch of TACTOSET, an injectable hyaluronic acid-enhanced bone repair therapy for bone voids and other bone defects caused by trauma or age-related degeneration. More news on: Anika Therapeutics, Inc., Healthcare sto...
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company leveraging its proprietary hyaluronic acid ("HA") technology platform to provide therapies across the Joint Preservation and Restoration continuum of care, today announced it has commenced the U.S. ...
News, Short Squeeze, Breakout and More Instantly...
Anika Therapeutics Inc. Company Name:
ANIK Stock Symbol:
NASDAQ Market:
Anika Therapeutics Inc. Website:
Integrity and its complete arthroscopic instrumentation platform are now fully available in the U.S., expanding Anika’s proprietary hyaluronic acid (HA) regenerative portfolio Over 300 surgeries completed during the limited market release, highlighting the growing interest and commerci...
2024-07-09 17:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-29 13:30:02 ET Stephens analyst issues EQUAL-WEIGHT recommendation for ANIK on May 29, 2024 12:00PM ET. The previous analyst recommendation was Equal-Weight. ANIK was trading at $25.32 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...